All News

Datopotamab deruxtecan was effective in patients with TROP2-QCS biomarker-positive tumors for non–small cell lung cancer

Presenter Krish Patel, MD, discusses the use of epcoritamab (Epkinly; AbbVie) and glofitamab (Columvi; Genentech) in aggressive B-cell lymphomas as monotherapies and in combination regimens.

Lazertinib with amivantamab was found to be similar in efficacy to osimertinib in the MARIPOSA study.

Experts debate over the most effective treatment pathway for Richter transformation, highlighting the risks and benefits of different cellular therapies.

MJH Life Sciences is celebrating its 25th anniversary.

The study authors suggest that annual screening for women aged 40 and older may be beneficial, but warn of the increased risk of false positive results.

Pharmacists are encouraged to leverage their trusted community role to help manage the anticipated health care burden from respiratory infections this season.

Treatment advancements highlight the curative potential of bone marrow transplants and emerging gene therapies.

Alessandra Ferrajoli, MD, discusses the importance of renal function for BCL2 inhibitors to avoid tumor lysis syndrome and cardiovascular history for BTK inhibitors to mitigate arrhythmia risks.

Individuals with a history of shingles was significantly and independently connected with a 20% higher risk of for subjective cognitive decline.

Full traditional approval follows accelerated approval of the medication last year.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Edaravone and dexborneol sublingual tablets are an innovative first drug to be designed for treatment of stroke and granted this designation.

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

Reid Merryman, MD, discusses the potential for minimal residual disease (MRD) to inform treatment decisions, identify lymphoma subgroups, and infer gene expression.

Disease-related factors include several prognostic scoring systems, such as DIPSS, whereas patient-related factors involve age, comorbidities, spleen size, and anemia.

New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.

A pharmacist with Allegheny Health Network discusses travel vaccines and what resources are valuable when determining which vaccinations are needed prior to travel.

ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.

Pharmacy professors discuss their experience implementing a TikTok activity in their curriculum, highlighting the benefits and challenges.

Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

Stefan Barta, MD, MS, MRCPCUK, discusses the potential role of biomarkers in predicting treatment outcomes, the emerging use of CAR T-cell therapy, and the benefits and challenges of combination therapies in managing T-cell lymphoma.

Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.

Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.

Rather than “trial-and-erroring” transplants for patients, experts should instead select transplants that are precise, personalized, and predictable.

The risk of therapy duplication with OTC and prescription PPIs can be lowered with an innovative, multi-faceted, and intentional approach by pharmacy teams and prescribers.

There is no significant impact on maternal or infant health outcomes when taking an additional iron supplement

Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.